Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours

European Journal of Nuclear Medicine

Volumn 25, Issue 1, 1998, Pages 79-83

  Adams, Stefan ^a   Baum, Richard ^a   Rink, Thomas ^a   Schumm Dräger, Petra Maria ^a   Usadel, Klaus Henning ^a   Hör, Gustav ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Dual radionuclide scintigraphy; Fluorine 18 fluorodeoxyglucose positron emission tomography; Gastroenteropancreatic tumours; Medullary thyroid carcinoma; Somatostatin receptor scintigraphy

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; PENTETATE INDIUM IN 111; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; SUCCIMER TC 99M; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM TUMOR; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMMUNOCYTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; SCINTIGRAPHY; THYROID MEDULLARY CARCINOMA; TUMOR LOCALIZATION;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL AGENTS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; PENTETIC ACID; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS; TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031910371     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050197     Document Type: Article

References (13)

1. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50: 5969-5977.
2. Scherübl H, Faiss S, Zimmer T, Riecken EO, Wiedenmann B. Neuroendocrine tumours of the gastroenteropancreatic system. I. Diagnostic advances. Oncology 1996; 19: 119-124.
3. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
4. Hoefnagel CA, Delprat CC, Zanin D, van der Schoot JB. New radionuclide tracers for the diagnostic and therapy of medullary thyroid carcinoma. Clin Nucl Med 1988; 13: 159-165.
5. Strauss LG, Ponti PS. The application of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
6. 131I. Nuklearmedizin 1995; 34: 127-134.
7. Lee CS. Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract. Cancer 1996; 78: 1881-1887.
8. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996; 37: 943-948.
9. Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 8: 187-191.
10. Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32: 1211-1218.
11. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-1774.
12. Busnardo B, Girelli ME, Simoini N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984; 53: 278-285.
13. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567-573.